A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer

Abstract Purpose  A phase I study of TCF therapy, which consists of paclitaxel (TXL: Taxol?) + cisplatin (CDDP) + 5-fluorouracil (5-FU), in advanced gastric cancer patients was performed to determine the recommended dose (RD) for a phase II study by checking the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of 5-FU above the fixed dose of TXL and CDDP.